Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Response to supraphysiological testosterone is predicted by a distinct AR cistrome [RNA-seq]

ABSTRACT: We generated RNA-Seq in CRPC PDX with SPT treatment

ORGANISM(S): Homo sapiens

PROVIDER: GSE188174 | GEO | 2022/04/06

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Response to supraphysiological testosterone is predicted by a distinct AR cistrome [ChIP-seq]

Project description:We generated transcription factor, histone modification ChIP-Seq in CRPC PDX with SPT treatment

2022-04-06 | GSE188173 | GEO

Response to supraphysiological testosterone is predicted by a distinct AR cistrome

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-04-06 | GSE188176 | GEO

Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts

Project description:The study aims to determine SPT effect on the CRPC growth and molecular alterations using LuCaP PDX CRPC models.

2019-07-16 | GSE124704 | GEO

Response to supraphysiological testosterone is predicted by a distinct AR cistrome

Project description:Response to supraphysiological testosterone is predicted by a distinct AR cistrome

| PRJNA777873 | ENA

Response to supraphysiological testosterone is predicted by a distinct AR cistrome [RNA-seq]

Project description:Response to supraphysiological testosterone is predicted by a distinct AR cistrome [RNA-seq]

| PRJNA777878 | ENA

Response to supraphysiological testosterone is predicted by a distinct AR cistrome [ChIP-seq]

Project description:Response to supraphysiological testosterone is predicted by a distinct AR cistrome [ChIP-seq]

| PRJNA777879 | ENA

Genome-wide maps of chromatin state in patient-derived model (PDX) of AR-positive or negative CRPC

Project description:We investigated the global OCT1 genomic signals using high-throughput chromatin immunoprecipitation sequencing (ChIP-seq) in a patient-derived model (PDX) of androgen receptor (AR)-negative or positive castration resistant prostate cancer (CRPC).

2022-04-20 | GSE193073 | GEO

Linking prostate cancer cell AR heterogeneity to distinct castration and Enzalutamide responses

Project description:Molecular mechanisms underlying resistance to androgen deprivation therapy (ADT) and, in particular, to antiandrogen Enzalutamide, in treating castration-resistant prostate cancer (CRPC), remain incompletely understood. Through screening >120 CRPC patient samples, we observed 3 expression patterns of androgen receptor (AR) protein: primarily nuclear (nuc-AR), mixed nuclear/cytoplasmic expression (nuc/cyto-AR), and low/no expression (AR-/lo). Xenograft CRPC modeling in 4 models (i.e., LNCaP, VCaP, LAPC4, and LAPC9) recapitulated the 3 AR expression patterns in castration-resistant tumors developed from parental androgen-dependent tumors. Strikingly, although the 3 CRPC models that retained AR expression (LNCaP, VCaP, and LAPC4) responded, to different levels and in different kinetics, to Enzalutamide, the AR-/lo LAPC9 CRPC was completely refractory to Enzalutamide. By combining whole-genome RNA-Seq and biochemical analyses together with experimental combinatorial therapy in the LNCaP and LAPC9 models, we identified BCL-2 as a critical therapeutic target in both AR+/hi and AR-/lo, Enzalutamide-resistant CRPC models.

2018-08-01 | GSE88752 | GEO

Spermine is a natural suppressor of AR signaling in castration-resistant prostate cancer

Project description:In castration-resistant prostate cancer (CRPC), clinical response to androgen receptor (AR) antagonists is limited mainly due to AR-variants expression and restored AR signaling. The metabolite spermine is most abundant in prostate and it decreases as prostate cancer progresses, but its functions remain poorly understood. Here, we show spermine inhibits full-length androgen receptor (AR-FL) and androgen receptor splice variant 7 (AR-V7) signaling and suppresses CRPC cell proliferation by directly binding and inhibiting protein arginine methyltransferase PRMT1. Spermine reduces H4R3me2a modification at the AR locus and suppresses AR binding as well as H3K27ac modification levels at AR target genes. Spermine supplementation restrains CRPC growth in vivo. PRMT1 inhibition also suppresses AR-FL and AR-V7 signaling and reduces CRPC growth. Collectively, we demonstrate spermine as an anticancer metabolite by inhibiting PRMT1 to transcriptionally inhibit AR-FL and AR-V7 signaling in CRPC, and we indicate spermine and PRMT1 inhibition as powerful strategies overcoming limitations of current AR-based therapies in CRPC.

2023-10-11 | MTBLS8034 | MetaboLights